Kala Pharmaceuticals, Inc.
KALADrugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Aug 14, 2026
16dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How KALA's past catalysts played out
KPI-121 Ophthalmic Suspension
Kerato Conjunctivitis Sicca
KPI-121 1% Ophthalmic Suspension dosed BID
Post Surgical Ocular Inflammation and Pain
KPI-121 0.25% Ophthalmic Suspension
Dry Eye Syndromes
KPI-121 1.0%
Ocular Infections, Irritations and Inflammations
KPI-121
Dry Eye Syndromes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KPI-121 Ophthalmic Suspension | Phase 3 | Kerato Conjunctivitis Sicca | - | - |
KPI-121 1% Ophthalmic Suspension dosed BID | Phase 3 | Post Surgical Ocular Inflammation and Pain | - | - |
KPI-121 0.25% Ophthalmic Suspension | Phase 3 | Dry Eye Syndromes | - | - |
KPI-121 1.0% | Phase 3 | Ocular Infections, Irritations and Inflammations | - | - |
KPI-121 | Phase 2 | Dry Eye Syndromes | - | - |
Dry Eye Syndromes
3 drugs in this indication
Kerato Conjunctivitis Sicca
1 drug in this indication
Post Surgical Ocular Inflammation and Pain
1 drug in this indication
Ocular Infections, Irritations and Inflammations
1 drug in this indication
Blepharitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kala Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Kala Pharmaceuticals, Inc.'s (KALA) pipeline across Phase 3, Phase 2. Its lead program is KPI-121 Ophthalmic Suspension (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kala Pharmaceuticals, Inc.'s next FDA catalyst?→
Kala Pharmaceuticals, Inc.'s (KALA) next tracked catalyst is a Earnings expected August 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KALA biotech catalysts?→
Add KALA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kala Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.